FDA Revises Paxlovid, Lagevrio EUAs Removing Positive COVID-19 Test Requirement
The FDA has revised the EUAs for Paxlovid and Lagevrio for the treatment of mild to moderate COVID-19.
The FDA has revised the EUAs for Paxlovid and Lagevrio for the treatment of mild to moderate COVID-19.
After that, COVID-19 would be treated as an endemic threat managed by more typical public health authorities
Organization’s International Health Regulations Emergency Committee met last week to discuss COVID-19
Additional protection against symptomatic infection provided for people who had previously received monovalent vaccine doses
Recent data show that the product is unlikely to be active against currently circulating SARS-CoV-2 variants.
Authors found low adherence to CDC recommendations for boosters, with older adults more likely to receive at least four mRNA COVID-19 vaccine doses
Proportion of overdose deaths did not increase in association with actions taken to ease access to buprenorphine
For children younger than 5 years, having any viral codetection or rhinovirus/enterovirus codetection significantly linked to severe illness
Reduction seen in mortality with COVID-19 convalescent plasma transfusion in randomized clinical trials, matched cohort studies
The preliminary safety signal was identified by the CDC’s Vaccine Safety Datalink.